Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation
SAN DIEGO, May 16, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its '721 formulation patent for NUPLAZID® (pimavanserin), Acadia's drug for the treatment of Parkinson's Disease Psychosis. In today's order, the Court ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated New Drug Application) filers.
"We are very pleased with today's decisive ruling in our favor, which provides patent protection for NUPLAZID 34 mg capsule formulation into 2038," said Catherine Owen Adams, Chief Executive Officer. "This result highlights Acadia's dedication to safeguarding our advancements in therapies for conditions with significant unmet medical needs."
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at Acadia.com and follow us on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential," "continue" and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) the impact of the court ruling on our business and our ability to defend ourselves in the future; (ii) the continued patent protection for NUPLAZID 34 mg capsule formulation; and (iii) and the anticipated timing for termination of such protections. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our ability to maintain, protect and enhance our intellectual property; the outcome of other existing and potential future lawsuits challenging our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-Q for the quarter ended March 31, 2025 as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250516870378/en/
Contacts
Investor Contact: Acadia Pharmaceuticals Inc.Al Kildani(858) 261-2872ir@acadia-pharm.com
Acadia Pharmaceuticals Inc.Jessica Tieszen(858) 261-2950ir@acadia-pharm.com
Media Contact: Acadia Pharmaceuticals Inc.Deb Kazenelson(818) 395-3043media@acadia-pharm.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Nucor (NUE) Exceeds Market Returns: Some Facts to Consider
In the latest market close, Nucor (NUE) reached $124.68, with a +1.75% movement compared to the previous day. This move outpaced the S&P 500's daily gain of 0.55%. On the other hand, the Dow registered a gain of 0.25%, and the technology-centric Nasdaq increased by 0.63%. Prior to today's trading, shares of the steel company had gained 2.01% over the past month. This has lagged the Basic Materials sector's gain of 4.58% and the S&P 500's gain of 6.29% in that time. The investment community will be closely monitoring the performance of Nucor in its forthcoming earnings report. In that report, analysts expect Nucor to post earnings of $2.21 per share. This would mark a year-over-year decline of 17.54%. Meanwhile, our latest consensus estimate is calling for revenue of $8.28 billion, up 2.55% from the prior-year quarter. For the full year, the Zacks Consensus Estimates project earnings of $7.88 per share and a revenue of $31.48 billion, demonstrating changes of -11.46% and +2.43%, respectively, from the preceding year. Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Nucor. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Nucor currently has a Zacks Rank of #3 (Hold). Investors should also note Nucor's current valuation metrics, including its Forward P/E ratio of 15.54. This valuation marks a premium compared to its industry's average Forward P/E of 10.69. Investors should also note that NUE has a PEG ratio of 0.78 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Steel - Producers industry was having an average PEG ratio of 0.94. The Steel - Producers industry is part of the Basic Materials sector. This industry currently has a Zacks Industry Rank of 68, which puts it in the top 28% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nucor Corporation (NUE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Musk Vs. Trump: Poll Says This Is The Person To Support In Feud, While Near Majority Say They Would Publicly Support Neither
A highly public feud between Tesla Inc (NASDAQ:TSLA) CEO Elon Musk and President Donald Trump took the world by storm last week and sent shares of the electric vehicle company lower. As the feud continues on, here's a look at where Benzinga readers stand. What Happened: A back-and-forth between Musk and Trump across social media platforms saw the two well-known individuals escalate a feud related to differences on the "Big Beautiful Bill." Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — The feud comes after Musk left his White House position working for the Department of Government Efficiency to spend more time working on his other companies, such as Tesla. Benzinga recently asked readers who they side with in the battle, which includes Musk criticizing the new debt the country will take on if the bill that Trump supports is passed by Congress. "In the feud between Donald Trump and Elon Musk, who are you more likely to publicly support?" Benzinga asked. Here are the results: Neither: 44% Elon Musk: 25% Donald Trump: 17% Both: 14% The poll found that a near majority said they would publicly support neither Trump or Musk in the feud between former friends. Of the two well-known candidates, Musk received the largest support with 25% of the poll, ranking ahead of Trump at 17%.Why It's Important: Over the weekend, the battle between Musk and Trump minimized some with the Tesla CEO deleting some of his tweets that brought some claims against the current president. Tweets about ending the SpaceX Dragon program were also deleted. A battle between Trump and Musk over the long run could see many losers, including the country's space program and the launch of robotaxis, with Musk a leader in both sectors and Trump able to slow down progress made by the billionaire. Tesla stock saw its largest one-day market capitalization drop last week on the heels of the feud. Tesla stock trades up 1.61% at $299.72 at publication on Monday versus a 52-week trading range of $167.42 to $488.54. The stock has fallen 15% over the last five days and is down 22% year-to-date in 2025. Read Next: Are you rich? Here's what Americans think you need to be considered wealthy. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? The study was conducted by Benzinga from June 5, 2025, through June 9, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 259 adults. Photo: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Musk Vs. Trump: Poll Says This Is The Person To Support In Feud, While Near Majority Say They Would Publicly Support Neither originally appeared on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
44 minutes ago
- Yahoo
McDonald's (MCD) Stock Sinks As Market Gains: What You Should Know
McDonald's (MCD) ended the recent trading session at $300.43, demonstrating a -1.43% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.55%. On the other hand, the Dow registered a gain of 0.25%, and the technology-centric Nasdaq increased by 0.63%. Coming into today, shares of the world's biggest hamburger chain had lost 2.29% in the past month. In that same time, the Retail-Wholesale sector gained 5.29%, while the S&P 500 gained 6.29%. Investors will be eagerly watching for the performance of McDonald's in its upcoming earnings disclosure. The company's upcoming EPS is projected at $3.13, signifying a 5.39% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $6.69 billion, indicating a 3.04% upward movement from the same quarter last year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $12.24 per share and a revenue of $26.35 billion, signifying shifts of +4.44% and +1.64%, respectively, from the last year. Investors should also take note of any recent adjustments to analyst estimates for McDonald's. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.25% rise in the Zacks Consensus EPS estimate. Currently, McDonald's is carrying a Zacks Rank of #3 (Hold). With respect to valuation, McDonald's is currently being traded at a Forward P/E ratio of 24.91. Its industry sports an average Forward P/E of 23.73, so one might conclude that McDonald's is trading at a premium comparatively. Meanwhile, MCD's PEG ratio is currently 3.18. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Retail - Restaurants was holding an average PEG ratio of 2.57 at yesterday's closing price. The Retail - Restaurants industry is part of the Retail-Wholesale sector. With its current Zacks Industry Rank of 185, this industry ranks in the bottom 25% of all industries, numbering over 250. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McDonald's Corporation (MCD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data
